| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung | 23 | 2023 | 849 | 4.170 |
Why?
|
| Pericytes | 8 | 2022 | 81 | 2.550 |
Why?
|
| Bronchoalveolar Lavage Fluid | 16 | 2022 | 117 | 2.420 |
Why?
|
| Pulmonary Fibrosis | 7 | 2022 | 157 | 2.220 |
Why?
|
| Acute Lung Injury | 5 | 2022 | 35 | 1.720 |
Why?
|
| HIV Infections | 7 | 2021 | 775 | 1.720 |
Why?
|
| Pulmonary Medicine | 6 | 2019 | 31 | 1.710 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2023 | 144 | 1.630 |
Why?
|
| Critical Care | 7 | 2019 | 263 | 1.600 |
Why?
|
| Fibronectins | 9 | 2012 | 130 | 1.550 |
Why?
|
| Membrane Glycoproteins | 5 | 2014 | 370 | 1.470 |
Why?
|
| Lung Injury | 5 | 2022 | 38 | 1.460 |
Why?
|
| Integrins | 15 | 2009 | 115 | 1.410 |
Why?
|
| Integrin alpha Chains | 5 | 2018 | 9 | 1.320 |
Why?
|
| Myofibroblasts | 4 | 2019 | 60 | 1.290 |
Why?
|
| Pneumonia, Ventilator-Associated | 3 | 2013 | 31 | 1.270 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2012 | 34 | 1.120 |
Why?
|
| Mice | 26 | 2023 | 8472 | 1.110 |
Why?
|
| Proteome | 3 | 2013 | 87 | 0.950 |
Why?
|
| Endothelial Cells | 2 | 2020 | 384 | 0.940 |
Why?
|
| Receptors, Immunologic | 3 | 2012 | 72 | 0.940 |
Why?
|
| Cell Adhesion | 8 | 2012 | 324 | 0.920 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2018 | 20 | 0.860 |
Why?
|
| Animals | 40 | 2023 | 20877 | 0.850 |
Why?
|
| HIV | 4 | 2017 | 53 | 0.840 |
Why?
|
| Pulmonary Emphysema | 3 | 2017 | 71 | 0.840 |
Why?
|
| Receptors, Cell Surface | 3 | 2014 | 248 | 0.840 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2021 | 121 | 0.820 |
Why?
|
| Lymphocytes | 3 | 2012 | 228 | 0.810 |
Why?
|
| Proteomics | 3 | 2014 | 246 | 0.800 |
Why?
|
| Biomarkers | 4 | 2017 | 1593 | 0.770 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 281 | 0.730 |
Why?
|
| Somatomedins | 2 | 2012 | 16 | 0.710 |
Why?
|
| Financial Management | 1 | 2019 | 10 | 0.710 |
Why?
|
| Membrane Proteins | 1 | 2023 | 617 | 0.650 |
Why?
|
| Trypsin Inhibitors | 1 | 2017 | 15 | 0.640 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2018 | 66 | 0.630 |
Why?
|
| Fibroblasts | 7 | 2018 | 902 | 0.610 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 61 | 0.610 |
Why?
|
| Diphtheria Toxin | 1 | 2017 | 18 | 0.600 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.600 |
Why?
|
| HIV-1 | 2 | 2013 | 177 | 0.590 |
Why?
|
| Macrophages | 1 | 2020 | 647 | 0.580 |
Why?
|
| Mouth | 1 | 2017 | 64 | 0.580 |
Why?
|
| Mice, Inbred C57BL | 11 | 2022 | 2790 | 0.580 |
Why?
|
| Pharynx | 1 | 2017 | 89 | 0.570 |
Why?
|
| Bleomycin | 4 | 2022 | 67 | 0.530 |
Why?
|
| Hyperoxia | 2 | 2012 | 27 | 0.510 |
Why?
|
| Humans | 48 | 2022 | 68525 | 0.510 |
Why?
|
| Skin Physiological Phenomena | 1 | 2014 | 13 | 0.490 |
Why?
|
| Transforming Growth Factor beta | 4 | 2018 | 384 | 0.480 |
Why?
|
| Sepsis | 2 | 2018 | 233 | 0.470 |
Why?
|
| Macrophages, Alveolar | 3 | 2020 | 34 | 0.460 |
Why?
|
| Leadership | 3 | 2019 | 135 | 0.460 |
Why?
|
| Inflammation | 6 | 2022 | 1030 | 0.450 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2013 | 42 | 0.450 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 110 | 0.450 |
Why?
|
| Cell Movement | 5 | 2009 | 630 | 0.440 |
Why?
|
| Mentors | 1 | 2013 | 81 | 0.440 |
Why?
|
| Up-Regulation | 7 | 2018 | 682 | 0.420 |
Why?
|
| Wound Healing | 1 | 2014 | 260 | 0.420 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2011 | 14 | 0.420 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 397 | 0.410 |
Why?
|
| Cytokines | 6 | 2016 | 866 | 0.410 |
Why?
|
| Collagen | 4 | 2023 | 636 | 0.400 |
Why?
|
| Myeloid Cells | 1 | 2012 | 57 | 0.400 |
Why?
|
| Cotinine | 1 | 2011 | 40 | 0.390 |
Why?
|
| Skin | 1 | 2014 | 451 | 0.390 |
Why?
|
| Disease Models, Animal | 6 | 2018 | 2550 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 510 | 0.380 |
Why?
|
| Cell Differentiation | 2 | 2013 | 1034 | 0.370 |
Why?
|
| Intensive Care Units | 2 | 2022 | 344 | 0.370 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 127 | 0.360 |
Why?
|
| Signal Transduction | 4 | 2013 | 2688 | 0.360 |
Why?
|
| Mice, Knockout | 8 | 2022 | 1692 | 0.350 |
Why?
|
| Fibrosis | 3 | 2019 | 371 | 0.350 |
Why?
|
| Cell Line | 8 | 2021 | 1752 | 0.350 |
Why?
|
| Sleep Medicine Specialty | 2 | 2018 | 2 | 0.340 |
Why?
|
| Sarcoidosis, Pulmonary | 2 | 2020 | 17 | 0.340 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 226 | 0.330 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 3 | 2012 | 3 | 0.320 |
Why?
|
| Faculty, Medical | 2 | 2019 | 110 | 0.320 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 163 | 0.320 |
Why?
|
| Muscle, Smooth | 3 | 2003 | 117 | 0.310 |
Why?
|
| Female | 19 | 2022 | 38015 | 0.310 |
Why?
|
| Adult | 16 | 2022 | 21375 | 0.310 |
Why?
|
| Male | 22 | 2022 | 37281 | 0.300 |
Why?
|
| Gene Expression Regulation | 5 | 2018 | 1293 | 0.300 |
Why?
|
| Radiation Pneumonitis | 1 | 2006 | 4 | 0.300 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 32 | 0.290 |
Why?
|
| Biomedical Research | 2 | 2015 | 310 | 0.280 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 46 | 0.280 |
Why?
|
| Middle Aged | 14 | 2018 | 21119 | 0.270 |
Why?
|
| Oxidative Stress | 1 | 2009 | 718 | 0.270 |
Why?
|
| Genome | 1 | 2004 | 54 | 0.250 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1753 | 0.250 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 1032 | 0.250 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 16 | 0.250 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2000 | 317 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 222 | 0.240 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 595 | 0.240 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 247 | 0.240 |
Why?
|
| Smoking | 2 | 2016 | 1449 | 0.230 |
Why?
|
| Virus Replication | 2 | 2020 | 104 | 0.230 |
Why?
|
| Extracellular Matrix | 3 | 2018 | 493 | 0.220 |
Why?
|
| Immunohistochemistry | 5 | 2008 | 1174 | 0.220 |
Why?
|
| Cells, Cultured | 8 | 2018 | 2673 | 0.220 |
Why?
|
| Thorax | 1 | 2022 | 49 | 0.220 |
Why?
|
| Nanotubes, Carbon | 2 | 2020 | 73 | 0.220 |
Why?
|
| Embryonic Development | 1 | 2023 | 100 | 0.210 |
Why?
|
| Hydroxyproline | 1 | 2022 | 33 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 245 | 0.210 |
Why?
|
| Endotoxins | 1 | 2022 | 76 | 0.210 |
Why?
|
| Physician's Role | 1 | 2003 | 116 | 0.210 |
Why?
|
| Receptors, Virus | 2 | 2018 | 20 | 0.210 |
Why?
|
| Physicians | 2 | 2022 | 324 | 0.210 |
Why?
|
| Tamoxifen | 1 | 2022 | 62 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2022 | 64 | 0.210 |
Why?
|
| Angiotensin II | 2 | 2001 | 220 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1548 | 0.200 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 127 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1173 | 0.190 |
Why?
|
| Gene Expression | 3 | 2015 | 770 | 0.190 |
Why?
|
| Virus Latency | 1 | 2020 | 10 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 2 | 2000 | 199 | 0.190 |
Why?
|
| Granuloma | 1 | 2020 | 21 | 0.190 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2020 | 28 | 0.190 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2020 | 31 | 0.190 |
Why?
|
| Oligopeptides | 2 | 1998 | 152 | 0.190 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 48 | 0.190 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2000 | 20 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2008 | 954 | 0.190 |
Why?
|
| Critical Illness | 2 | 2013 | 191 | 0.190 |
Why?
|
| Societies, Medical | 1 | 2003 | 403 | 0.190 |
Why?
|
| Biopolymers | 1 | 2000 | 21 | 0.180 |
Why?
|
| Vitronectin | 2 | 2000 | 12 | 0.180 |
Why?
|
| Escherichia coli | 1 | 2022 | 368 | 0.180 |
Why?
|
| Relative Value Scales | 1 | 2019 | 8 | 0.180 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2016 | 45 | 0.180 |
Why?
|
| Young Adult | 3 | 2018 | 5708 | 0.180 |
Why?
|
| Fee-for-Service Plans | 1 | 2019 | 24 | 0.180 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 29 | 0.180 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 37 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2017 | 113 | 0.180 |
Why?
|
| Reimbursement, Incentive | 1 | 2019 | 25 | 0.180 |
Why?
|
| Negotiating | 1 | 2019 | 18 | 0.180 |
Why?
|
| Research Support as Topic | 1 | 2019 | 58 | 0.180 |
Why?
|
| Efficiency | 1 | 2019 | 49 | 0.180 |
Why?
|
| Organizational Innovation | 1 | 2019 | 55 | 0.180 |
Why?
|
| Clinical Medicine | 1 | 2019 | 20 | 0.170 |
Why?
|
| Personnel Management | 1 | 2018 | 11 | 0.170 |
Why?
|
| Sexism | 1 | 2018 | 11 | 0.170 |
Why?
|
| Epithelial Cells | 3 | 2014 | 431 | 0.170 |
Why?
|
| Integrin alpha6beta4 | 1 | 2018 | 1 | 0.170 |
Why?
|
| Virus Attachment | 1 | 2018 | 3 | 0.170 |
Why?
|
| Integrin alpha6 | 1 | 2018 | 2 | 0.170 |
Why?
|
| Adenoviruses, Human | 1 | 2018 | 12 | 0.170 |
Why?
|
| Laminin | 1 | 2018 | 62 | 0.160 |
Why?
|
| Apoptosis | 4 | 2008 | 1640 | 0.160 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2018 | 4 | 0.160 |
Why?
|
| Aged | 6 | 2018 | 14842 | 0.160 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2017 | 1 | 0.160 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2018 | 16 | 0.160 |
Why?
|
| Actins | 2 | 2013 | 249 | 0.160 |
Why?
|
| Aorta | 2 | 2000 | 316 | 0.160 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2018 | 33 | 0.160 |
Why?
|
| Curriculum | 2 | 2015 | 575 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.160 |
Why?
|
| Muscle Contraction | 1 | 1998 | 210 | 0.160 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2018 | 106 | 0.160 |
Why?
|
| Flow Cytometry | 2 | 2011 | 489 | 0.150 |
Why?
|
| Emergency Medicine | 1 | 2018 | 88 | 0.150 |
Why?
|
| Gene Deletion | 1 | 2018 | 235 | 0.150 |
Why?
|
| Sarcoidosis | 1 | 2017 | 77 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 447 | 0.150 |
Why?
|
| Capillary Permeability | 1 | 2017 | 69 | 0.150 |
Why?
|
| Reference Values | 3 | 2014 | 579 | 0.150 |
Why?
|
| Immune System | 1 | 2017 | 63 | 0.150 |
Why?
|
| Ductus Arteriosus | 1 | 1996 | 13 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 214 | 0.140 |
Why?
|
| Pediatrics | 1 | 2019 | 341 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 232 | 0.140 |
Why?
|
| Bronchoscopy | 3 | 2016 | 147 | 0.140 |
Why?
|
| United States | 4 | 2022 | 7335 | 0.140 |
Why?
|
| Leukocytes | 1 | 2016 | 99 | 0.140 |
Why?
|
| Models, Animal | 1 | 2017 | 252 | 0.140 |
Why?
|
| Tenascin | 1 | 1995 | 39 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 507 | 0.130 |
Why?
|
| Neutrophils | 2 | 2012 | 204 | 0.130 |
Why?
|
| Ligands | 2 | 2008 | 317 | 0.130 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2015 | 2 | 0.130 |
Why?
|
| Barotrauma | 1 | 1995 | 3 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 498 | 0.130 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 23 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 492 | 0.130 |
Why?
|
| CD4 Antigens | 1 | 2014 | 42 | 0.130 |
Why?
|
| Jurkat Cells | 2 | 2008 | 59 | 0.130 |
Why?
|
| Asthma | 1 | 2019 | 345 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 244 | 0.120 |
Why?
|
| Career Choice | 1 | 2015 | 98 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 371 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2017 | 2356 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 139 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 69 | 0.120 |
Why?
|
| Aging | 2 | 1996 | 911 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 94 | 0.110 |
Why?
|
| Base Sequence | 3 | 2004 | 1015 | 0.110 |
Why?
|
| Rats | 7 | 2001 | 5300 | 0.110 |
Why?
|
| Protein Interaction Maps | 1 | 2013 | 30 | 0.110 |
Why?
|
| Breath Tests | 1 | 2012 | 23 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 62 | 0.110 |
Why?
|
| Immunoassay | 1 | 2012 | 64 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 368 | 0.110 |
Why?
|
| Monitoring, Physiologic | 2 | 2011 | 219 | 0.110 |
Why?
|
| Mannose | 1 | 2012 | 9 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2013 | 218 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 765 | 0.110 |
Why?
|
| Molecular Sequence Data | 3 | 2004 | 1446 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 261 | 0.110 |
Why?
|
| Child | 2 | 2022 | 6400 | 0.110 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2012 | 48 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2015 | 3702 | 0.110 |
Why?
|
| Acetylglucosamine | 1 | 2012 | 46 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2012 | 90 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2012 | 56 | 0.100 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2002 | 11 | 0.100 |
Why?
|
| Calcitonin | 1 | 2011 | 21 | 0.100 |
Why?
|
| Virion | 2 | 2002 | 31 | 0.100 |
Why?
|
| Chemokines | 1 | 2012 | 119 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2021 | 237 | 0.100 |
Why?
|
| HIV Seropositivity | 2 | 2006 | 65 | 0.100 |
Why?
|
| Animals, Newborn | 3 | 2003 | 396 | 0.100 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2011 | 46 | 0.100 |
Why?
|
| Chimera | 1 | 2010 | 33 | 0.100 |
Why?
|
| Kidney | 3 | 2004 | 945 | 0.100 |
Why?
|
| Monocytes | 1 | 2012 | 210 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2011 | 105 | 0.100 |
Why?
|
| Transfection | 3 | 2005 | 782 | 0.100 |
Why?
|
| Thymus Gland | 1 | 2010 | 97 | 0.100 |
Why?
|
| Oximetry | 1 | 1990 | 29 | 0.100 |
Why?
|
| Allergens | 1 | 2010 | 54 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2011 | 117 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1663 | 0.090 |
Why?
|
| Mesoderm | 2 | 2003 | 231 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2004 | 230 | 0.090 |
Why?
|
| DNA, Complementary | 2 | 2004 | 251 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 180 | 0.090 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2009 | 7 | 0.090 |
Why?
|
| Peroxiredoxins | 1 | 2009 | 34 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2011 | 447 | 0.090 |
Why?
|
| Lymph Nodes | 2 | 2002 | 258 | 0.090 |
Why?
|
| Neurons | 1 | 1995 | 881 | 0.090 |
Why?
|
| Receptors, Fibronectin | 3 | 2000 | 6 | 0.090 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 32 | 0.090 |
Why?
|
| Receptors, Vitronectin | 3 | 2000 | 11 | 0.090 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 37 | 0.090 |
Why?
|
| Ligation | 2 | 2018 | 83 | 0.090 |
Why?
|
| Species Specificity | 1 | 2009 | 302 | 0.090 |
Why?
|
| Morphogenesis | 1 | 2009 | 158 | 0.090 |
Why?
|
| Intestines | 1 | 2009 | 114 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2011 | 714 | 0.080 |
Why?
|
| Organizational Culture | 2 | 2019 | 59 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 60 | 0.080 |
Why?
|
| Collagen Type IV | 1 | 2008 | 28 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2014 | 2004 | 0.080 |
Why?
|
| Integrin beta Chains | 1 | 2008 | 7 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2798 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2001 | 2083 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 75 | 0.080 |
Why?
|
| Collagen Type I | 1 | 2008 | 175 | 0.080 |
Why?
|
| Selectins | 2 | 2016 | 3 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2264 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 188 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4843 | 0.070 |
Why?
|
| Abnormalities, Radiation-Induced | 1 | 2006 | 4 | 0.070 |
Why?
|
| Washington | 1 | 2006 | 27 | 0.070 |
Why?
|
| Pneumonia | 1 | 2008 | 110 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 27 | 0.070 |
Why?
|
| 3T3 Cells | 2 | 2004 | 124 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2006 | 52 | 0.070 |
Why?
|
| Prevalence | 1 | 2011 | 1609 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2003 | 282 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2004 | 126 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 434 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 3 | 2000 | 852 | 0.070 |
Why?
|
| Staurosporine | 1 | 2005 | 19 | 0.070 |
Why?
|
| Chromones | 1 | 2005 | 33 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 331 | 0.060 |
Why?
|
| Morpholines | 1 | 2005 | 79 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2004 | 10 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 132 | 0.060 |
Why?
|
| Adhesins, Bacterial | 1 | 2004 | 13 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2008 | 1199 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 91 | 0.060 |
Why?
|
| Bacterial Adhesion | 1 | 2004 | 33 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2004 | 52 | 0.060 |
Why?
|
| Exons | 1 | 2004 | 122 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1745 | 0.060 |
Why?
|
| Flavonoids | 1 | 2005 | 109 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2004 | 136 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 144 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 188 | 0.060 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 5 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2004 | 11 | 0.060 |
Why?
|
| HIV Antigens | 1 | 2004 | 9 | 0.060 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 10 | 0.060 |
Why?
|
| Smad Proteins | 1 | 2004 | 25 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 337 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 161 | 0.060 |
Why?
|
| Keratins | 1 | 2003 | 48 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2004 | 93 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2004 | 220 | 0.060 |
Why?
|
| Pneumocystis | 2 | 1993 | 3 | 0.060 |
Why?
|
| Protein Conformation | 1 | 2004 | 362 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 301 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2003 | 282 | 0.060 |
Why?
|
| Medical Laboratory Science | 1 | 2003 | 8 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 1082 | 0.060 |
Why?
|
| Sex Factors | 2 | 2018 | 1265 | 0.060 |
Why?
|
| Information Systems | 1 | 2003 | 45 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2004 | 149 | 0.060 |
Why?
|
| North America | 1 | 2022 | 111 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 455 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2004 | 546 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2002 | 26 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2004 | 244 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2014 | 880 | 0.050 |
Why?
|
| Genotype | 1 | 2004 | 785 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 272 | 0.050 |
Why?
|
| Certification | 1 | 2003 | 66 | 0.050 |
Why?
|
| Canada | 1 | 2003 | 266 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 742 | 0.050 |
Why?
|
| Cell Survival | 1 | 2005 | 901 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 319 | 0.050 |
Why?
|
| Protein Binding | 1 | 2005 | 1027 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 3256 | 0.050 |
Why?
|
| DNA | 1 | 2004 | 597 | 0.050 |
Why?
|
| Workload | 1 | 2003 | 103 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 614 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 659 | 0.050 |
Why?
|
| Employment | 1 | 2003 | 154 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2004 | 627 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2003 | 185 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2004 | 597 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 169 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 107 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2000 | 24 | 0.050 |
Why?
|
| Logistic Models | 2 | 2014 | 1419 | 0.050 |
Why?
|
| Thromboplastin | 1 | 2000 | 21 | 0.050 |
Why?
|
| Carbon Tetrachloride | 1 | 2000 | 15 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 102 | 0.050 |
Why?
|
| Heparitin Sulfate | 1 | 2000 | 20 | 0.050 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2000 | 8 | 0.050 |
Why?
|
| Pulmonary Alveoli | 1 | 2000 | 62 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2000 | 165 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2000 | 58 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2000 | 59 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 700 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1851 | 0.040 |
Why?
|
| Epitopes | 1 | 2000 | 146 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2000 | 103 | 0.040 |
Why?
|
| Colorado | 1 | 2019 | 26 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 442 | 0.040 |
Why?
|
| Genes, Wilms Tumor | 1 | 1999 | 5 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 447 | 0.040 |
Why?
|
| Pyroptosis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cecum | 1 | 2018 | 39 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 346 | 0.040 |
Why?
|
| Phenylephrine | 1 | 1998 | 61 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 85 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 290 | 0.040 |
Why?
|
| Mucoproteins | 1 | 1998 | 3 | 0.040 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1998 | 5 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2018 | 42 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2000 | 523 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2018 | 50 | 0.040 |
Why?
|
| Cricetulus | 1 | 2018 | 98 | 0.040 |
Why?
|
| Serotonin | 1 | 1998 | 144 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1998 | 52 | 0.040 |
Why?
|
| CHO Cells | 1 | 2018 | 161 | 0.040 |
Why?
|
| Endothelium | 1 | 1998 | 98 | 0.040 |
Why?
|
| Synapses | 1 | 2000 | 222 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 1998 | 97 | 0.040 |
Why?
|
| Antibodies | 1 | 1998 | 241 | 0.040 |
Why?
|
| Astrocytes | 1 | 2000 | 270 | 0.040 |
Why?
|
| Neuronal Plasticity | 1 | 2000 | 274 | 0.040 |
Why?
|
| Heart | 1 | 2001 | 850 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 74 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2008 | 7028 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 1996 | 76 | 0.040 |
Why?
|
| Tracheal Neoplasms | 1 | 1996 | 3 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2016 | 20 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1996 | 12 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 69 | 0.040 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 5 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2016 | 15 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2016 | 63 | 0.040 |
Why?
|
| Angiopoietin-1 | 1 | 2016 | 12 | 0.040 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 24 | 0.040 |
Why?
|
| Immunity | 1 | 2016 | 67 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 248 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 1993 | 85 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 1995 | 6 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 123 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 329 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 94 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 73 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 562 | 0.030 |
Why?
|
| RNA | 1 | 2016 | 171 | 0.030 |
Why?
|
| Myocardium | 1 | 2001 | 1204 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 302 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 1998 | 320 | 0.030 |
Why?
|
| Gestational Age | 1 | 1996 | 389 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1995 | 176 | 0.030 |
Why?
|
| Respiratory Mechanics | 1 | 1995 | 33 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 189 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 320 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1998 | 458 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 357 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 242 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 306 | 0.030 |
Why?
|
| Chickens | 1 | 1995 | 232 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1995 | 190 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 381 | 0.030 |
Why?
|
| Pentamidine | 1 | 1993 | 7 | 0.030 |
Why?
|
| Radiography | 1 | 2014 | 572 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 57 | 0.030 |
Why?
|
| Sputum | 1 | 1993 | 51 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1993 | 74 | 0.030 |
Why?
|
| Agglutination | 1 | 2012 | 3 | 0.030 |
Why?
|
| Maleimides | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2012 | 8 | 0.030 |
Why?
|
| Polymethacrylic Acids | 1 | 2012 | 19 | 0.030 |
Why?
|
| Models, Biological | 1 | 2017 | 981 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2012 | 79 | 0.030 |
Why?
|
| Survival Rate | 1 | 1995 | 1055 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 187 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.030 |
Why?
|
| Hemoglobins, Abnormal | 1 | 1990 | 5 | 0.020 |
Why?
|
| Lighting | 1 | 1990 | 9 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 1990 | 20 | 0.020 |
Why?
|
| Coloring Agents | 1 | 1990 | 66 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1425 | 0.020 |
Why?
|
| History, 20th Century | 1 | 1990 | 248 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1039 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1860 | 0.020 |
Why?
|
| Anemia | 1 | 1990 | 104 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 2093 | 0.020 |
Why?
|
| Fetus | 1 | 2009 | 157 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 219 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 328 | 0.020 |
Why?
|
| Risk Factors | 2 | 1995 | 5719 | 0.020 |
Why?
|
| Treponema pallidum | 1 | 2004 | 5 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 17 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2001 | 59 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 272 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2001 | 80 | 0.010 |
Why?
|
| Integrin alpha1beta1 | 1 | 2000 | 5 | 0.010 |
Why?
|
| Osteopontin | 1 | 2000 | 28 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2001 | 146 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2000 | 45 | 0.010 |
Why?
|
| Long-Term Potentiation | 1 | 2000 | 53 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2000 | 86 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2000 | 138 | 0.010 |
Why?
|
| Indomethacin | 1 | 2000 | 107 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1999 | 47 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2000 | 236 | 0.010 |
Why?
|
| Memory | 1 | 2000 | 214 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 100 | 0.010 |
Why?
|
| Learning | 1 | 2000 | 186 | 0.010 |
Why?
|
| Kinetics | 1 | 2000 | 1047 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1999 | 52 | 0.010 |
Why?
|
| Peptides | 1 | 2001 | 455 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2000 | 313 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 626 | 0.010 |
Why?
|
| Hippocampus | 1 | 2000 | 471 | 0.010 |
Why?
|
| Melanoma | 1 | 2000 | 335 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 98 | 0.010 |
Why?
|
| Pneumocystis Infections | 1 | 1993 | 2 | 0.010 |
Why?
|
| Aerosols | 1 | 1993 | 42 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1996 | 7264 | 0.010 |
Why?
|
| Brain | 1 | 2000 | 2175 | 0.010 |
Why?
|